Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557605 | 0.97 | HPGD (0.55) | HPGDALDH1A1POLBADORA2AGRIA3 | |
| SCHEMBL557606 | 0.84 | HPGD (0.42) | HPGD | |
| SCHEMBL557499 | 0.82 | VNN1 (0.45) | HPGD | |
| SCHEMBL10174957 | 0.76 | PLAU (0.37) | HPGDALDH1A1 | |
| SCHEMBL17350917 | 0.74 | CSF1R (0.41) | HPGDALDH1A1 | |
| SCHEMBL17350560 | 0.74 | RIPK2 (0.44) | ALDH1A1AKT1AKT2 | |
| SCHEMBL557497 | 0.74 | JMJD6 (0.42) | HPGDALDH1A1AKT1AKT2 | |
| SCHEMBL23675137 | 0.74 | HPGD (0.64) | HPGDALDH1A1POLB | |
| SCHEMBL31525 | 0.74 | HPGD (0.77) | HPGDALDH1A1ADORA2A | |
| SCHEMBL23675321 | 0.74 | HPGD (1.00) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197880-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8859583-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8076354-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-13 | — | — | US | disclosed |
| US-20100331296-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | HPGD 1667/4885ALDH1A1 3442/4885POLB 4038/4885 |
| US-20100331296-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | HPGD 1667/4885ALDH1A1 3442/4885POLB 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.